Hypera (HYPE3) Aktievy
Hypera S.A. är verksamt som ett läkemedelsföretag i Brasilien. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 4/6 |
HYPE3 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hypera S.A. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | R$22.69 |
| 52 veckors högsta | R$28.87 |
| 52 veckors lägsta | R$20.66 |
| Beta | 0 |
| 1 månads förändring | -1.35% |
| 3 månaders förändring | -4.78% |
| 1 års förändring | -7.20% |
| 3 års förändring | -44.93% |
| 5 års förändring | -37.32% |
| Förändring sedan börsintroduktionen | 171.74% |
Senaste nyheter och uppdateringar
Analysartikel • May 07
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...
Uppdatering av berättelse • Feb 05
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Recent updates
Analysartikel • May 07
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...Uppdatering av berättelse • Feb 05
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Uppdatering av berättelse • Jan 20
HYPE3: Slight Index Exit And Firm P/E Outlook Will Support Upside
Analysts have nudged their price target for Hypera slightly lower to reflect small adjustments in fair value, discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a modest trim of about R$0.15 per share. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how some index and benchmark aware investors treat the stock (Key Developments).Uppdatering av berättelse • Jan 05
HYPE3: Future P/E Multiple Expansion Will Support Further Upside Potential
Analysts have slightly increased their price target on Hypera to reflect updated fair value estimates and adjustments to revenue growth, profit margin expectations, and future P/E assumptions. What's in the News Hypera S.A. is scheduled to hold a board meeting on Dec 11, 2025, which may address governance, capital allocation, or operational planning (company event filing).Analysartikel • Dec 28
Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Uppdatering av berättelse • Dec 15
HYPE3: Future P E Expansion Will Support Further Upside Potential
Analysts have slightly raised their price target on Hypera to $30.24 from $30.14, citing modestly stronger revenue growth expectations that more than offset a small downward revision in projected profit margins and a higher implied future P/E multiple. Valuation Changes Fair Value Estimate has risen slightly from R$30.14 to R$30.24 per share, reflecting a modestly higher intrinsic valuation.Analysartikel • Dec 01
What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 9x, you may consider Hypera...Uppdatering av berättelse • Dec 01
HYPE3: Future P/E Expansion Signals Continued Upside Potential
Analysts have increased their price target for Hypera from $29.59 to $30.14, citing revised estimates that reflect a slightly higher discount rate as well as updated projections for revenue growth and profit margin. Valuation Changes Fair Value: Increased slightly from R$29.59 to R$30.14 per share.Analysartikel • Nov 05
Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think
Hypera S.A.'s ( BVMF:HYPE3 ) stock showed strength, with investors undeterred by its weak earnings report. We think...Analysartikel • Sep 05
Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Aug 10
Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next
It's been a sad week for Hypera S.A. ( BVMF:HYPE3 ), who've watched their investment drop 10% to R$23.19 in the week...Analysartikel • Jun 15
The Price Is Right For Hypera S.A. (BVMF:HYPE3)
With a price-to-earnings (or "P/E") ratio of 21.7x Hypera S.A. ( BVMF:HYPE3 ) may be sending very bearish signals at...Analysartikel • Apr 23
Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Mar 27
Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Hypera S.A.'s ( BVMF:HYPE3 ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Ny berättelse • Mar 23
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.Analysartikel • Feb 24
Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E
With a median price-to-earnings (or "P/E") ratio of close to 8x in Brazil, you could be forgiven for feeling...Analysartikel • Nov 21
More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%
To the annoyance of some shareholders, Hypera S.A. ( BVMF:HYPE3 ) shares are down a considerable 27% in the last month...Analysartikel • Nov 14
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Oct 03
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
There wouldn't be many who think Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10x is worth a...Analysartikel • Jul 13
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Jun 20
Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10.9x right now seems...Analysartikel • Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Hypera S.A. ( BVMF:HYPE3 ) had a good week, as its shares rose 3.3% to close at R$34.10 following the...Analysartikel • Feb 21
Is Hypera (BVMF:HYPE3) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Jan 09
Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Dec 22
Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 12.7x right now seems...Analysartikel • Nov 02
Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Aug 27
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Jul 21
Is Hypera (BVMF:HYPE3) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Apr 15
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Feb 19
With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Jan 03
We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Oct 11
Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Jul 31
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Hypera S.A. ( BVMF:HYPE3 ) shareholders, because the company has just released its latest...Analysartikel • Jul 19
Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jun 28
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Apr 14
Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysartikel • Mar 25
I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Analysartikel • Mar 04
Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 13x might make it look like a sell right now...Aktieägarnas avkastning
| HYPE3 | BR Pharmaceuticals | BR Marknad | |
|---|---|---|---|
| 7D | -1.5% | 0.8% | 0.2% |
| 1Y | -7.2% | 22.2% | 14.8% |
Avkastning vs industri: HYPE3 presterade sämre än BR Pharmaceuticals branschen som gav 22.2 % under det senaste året.
Avkastning vs Marknaden: HYPE3 presterade sämre än BR marknaden som gav 14.8 % under det senaste året.
Prisvolatilitet
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 8.4% |
| 10% least volatile stocks in BR Market | 1.9% |
Stabil aktiekurs: HYPE3 har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för BR.
Volatilitet över tid: HYPE3 s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1999 | 10,564 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. är verksamt som ett läkemedelsföretag i Brasilien. Företaget erbjuder receptbelagda produkter under varumärkena Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex - A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma och velunid. Företaget tillhandahåller också solskyddande och fuktgivande hudvårdsprodukter under varumärkena Mantecorp Skincare, liknande produkter under varumärkena Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum och Torsilax; och receptfria läkemedel under varumärkena Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil och Neosaldina, samt liknande och generiska läkemedel under varumärket Neo Química.
Hypera S.A. Sammanfattning av grunderna
| HYPE3 grundläggande statistik | |
|---|---|
| Börsvärde | R$15.96b |
| Vinst(TTM) | R$1.20b |
| Intäkter(TTM) | R$7.70b |
13.3x
P/E-förhållande2.1x
P/S-förhållandeÄr HYPE3 övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| HYPE3 resultaträkning (TTM) | |
|---|---|
| Intäkter | R$7.70b |
| Kostnad för intäkter | R$3.15b |
| Bruttovinst | R$4.55b |
| Övriga kostnader | R$3.35b |
| Intäkter | R$1.20b |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Aug 06, 2026
| Vinst per aktie (EPS) | 1.70 |
| Bruttomarginal | 59.04% |
| Nettovinstmarginal | 15.53% |
| Skuld/egenkapitalförhållande | 74.6% |
Hur har HYPE3 utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
5.2%
Aktuell utdelningsavkastning62%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 12:11 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Hypera S.A. bevakas av 22 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |